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Abstract: Alzheimer’s disease (AD) is incredibly common. Increasing longevity ensures 
its prevalence will rise even further. Ongoing efforts to understand AD pathogenesis reveal 
numerous tantalizing leads. Formulating a comprehensive AD pathogenesis theory capable of 
incorporating these disparate leads, though, has proven difﬁ  cult. This review discusses current 
attempts to formulate a comprehensive AD pathogenesis theory. In doing so, it focuses on clinical 
and molecular relationships between AD and aging. A better understanding of these relationships 
could inform and impact future development of AD-directed treatment strategies.
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Introduction
Alzheimer’s disease (AD) is the most common disease of aging. Countless clinicians 
and scientists have dedicated careers to its investigation. For some time the ﬁ  eld has 
been too large to comprehensively summarize. While this review broadly discusses 
both molecular and clinical AD-relevant themes, it considers these themes within 
the narrower context of aging. By focusing in this way, it hopes to provide a better 
understanding of aging-AD relationships. Considering AD as a disease of aging provides 
perspective on recent therapeutic development efforts, which are discussed later on. 
First, though, it is necessary to deﬁ  ne AD and describe why it is so intimately related 
to aging. While doing so, it is necessary to consider which is more appropriate – to 
consider AD a condition of aging, or to consider it as a distinct disease entity. Although 
this argument is largely a semantic one, it does have important implications for future 
AD research.
What is Alzheimer’s disease?
This review will ﬁ  rst consider the term “Alzheimer’s disease”. This is a worthwhile 
endeavor because AD perspectives abound. Affected patients and their family members 
may not distinguish AD from the generic dementia clinical syndrome. Physicians not 
specializing in AD often don’t go much further, using it as a default diagnosis for 
persons dementing despite negative diagnostic tests. To AD sub-specialists able to 
identify and categorize different patterns of cognitive decline, AD is less a diagnosis 
of exclusion and more a recognizable entity. AD sub-specialists can predict with 
reasonable accuracy the histopathologic features existing within the brains of those 
with an AD-consistent clinical syndrome (Gearing et al 1995). However, the pathogenic 
relevance of these histopathologic features is itself unclear.
The ﬁ  rst deﬁ  ned histopathologic features of AD were extracellular amyloid plaques 
and intracellular neuroﬁ  brillary tangles. More recently recognized histopathologic 
features include synaptic degeneration, hippocampal neuronal loss, and aneuploidy. 
AD histopathologic criteria, though, currently take into account only plaques and 
tangles. Several AD histopathologic criteria are commonly used (Khachaturian 1985; 
Mirra et al 1991; Consensus Criteria 1997). Approximately 90% of the time, when 
pathologists evaluate brains from persons diagnosed with AD by trained clinicians, Clinical Interventions in Aging 2007:2(3) 348
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enough plaques and tangles are found to meet histopathologic 
diagnostic standards (Gearing et al 1995). Interestingly, 
for some time pathologists have recognized non-demented 
elderly individuals will also qualify for a histopathologic 
diagnosis of AD (reviewed in Swerdlow 2006). This has 
caused fundamental problems for the AD ﬁ  eld. If plaque-
tangle quantity represents the AD “gold standard”, then 
clinical dementia becomes less relevant to the diagnosis.
De-emphasizing dementia as a required component 
raises several conceptual questions. First, how should one 
consider deceased individuals with plaque-laden brains but 
no dementia? The term “preclinical AD” is often used in 
these situations (Price et al 2001). Preclinical AD assumes 
histopathologic changes can precede clinical changes, and 
that if preclinical AD subjects lived longer dementia would 
manifest. Until recently this assumption has not been test-
able. The advent of in vivo plaque and plaque-tangle imaging 
may facilitate more critical assessment of this hypothesis. To 
date, such imaging has corroborated the pathology literature, 
in that non-demented elderly subjects often have plaque 
burdens equivalent to those with clinically diagnosed AD 
(Shoghi-Jadid et al 2002; Klunk et al 2004; Fagan et al 2006; 
Rentz et al 2006).
The second conceptual question relates to how many 
people either have AD or the potential to get AD. Certainly, 
how to address this question depends heavily on the deﬁ  nition 
used. If histopathology represents the gold standard, then up 
to 95% of those making it over 100 years of age have AD 
(Jicha et al 2005). One large survey of brains from persons 
over 85 found at least some degree of AD histopathology in 
all brains examined (Polvikoski et al 2005). A possible inter-
pretation of this is that all individuals, should they live long 
enough, have the potential to develop AD. While this point 
is also not testable, it is minimally relevant. Rather, it is more 
important to consider whether in the most at-risk demographic 
groups it becomes more common to have AD than not to have 
AD. This does appear to be the case. Since approximately 
75%–90% of centenarians have a dementia syndrome and 
85%–95% meet at least minimal histopathologic criteria 
for AD (Mizutani and Shamada 1992; Thomassen et al 
1998; Blansjaar et al 2000; Perls 2004; Jicha et al 2005), it 
seems reasonable to conclude centenarians are expected to 
have AD, and those who do not have it are the exception. 
Therefore, it is worth considering that at some point in the 
aging continuum AD ceases to become a disease because it 
becomes the norm.
The third conceptual question relates to the fact individuals 
commonly experience age-related revision of their cognitive 
skills. The neuropsychology literature suggests that upon 
reaching adulthood, insidious cognitive changes ensue 
(Snowdon et al 1996; Smyth et al 2004). These changes, 
which occur over decades, generally represent decline from 
previously higher levels of function as opposed to lateral 
shifts in cognitive strategies. While associated with at most 
subtle functional consequences not felt to be clinically 
relevant on an individual basis, it is worthwhile considering 
whether these changes do in fact represent part of an AD 
continuum. The relevance of this question is emphasized by 
the recently evolved concept of mild cognitive impairment 
(MCI) (Petersen et al 1999). MCI was originally intended 
to define a transitional state between normal cognition 
and dementia. Retrospective perspectives now suggest the 
majority of those with MCI are actually manifesting AD in 
its earliest recognizable clinical form (Morris 2006). The 
operational deﬁ  nition of MCI is similar to that of an older 
term, age-associated cognitive decline (AACD) (Levy 1994). 
AACD was formulated to classify those with “benign” 
cognitive changes. The main difference between AACD and 
MCI is therefore one of perspective. AACD was intended 
as an optimistic diagnosis, whereas MCI is considerably 
more pessimistic. Whether the physiology underlying age-
associated cognitive changes is fundamentally different from 
that underlying AD-associated cognitive change remains 
unknown.
It is now common to lump under the AD umbrella 
all dementia syndromes manifesting plaque and tangle 
accumulation. This in turn has driven classiﬁ  cation of various 
AD subtypes. Dementia of the Alzheimer’s Type (DAT) 
corresponds to the classic presenile form identiﬁ  ed by Alois 
Alzheimer. Senile dementia of the Alzheimer’s Type (SDAT) 
includes individuals that until the 1970’s may have been 
assigned a diagnosis of senility, hardening of the arteries, or 
just getting older. Late-onset AD (LOAD) generally applies 
to those developing signs and symptoms after the age of 65. 
Early-onset AD variably refers to those developing signs or 
symptoms before the age of 55, 60, or 65. The exact upper 
age limit is therefore arbitrarily deﬁ  ned. Familial AD (FAD) 
loosely refers to those AD subjects with a positive AD family 
history, but without additional clariﬁ  cation this designation 
is confusing. The reason is that if the simple presence of a 
single affected relative is enough to qualify a patient for FAD, 
then FAD is incredibly common. If more stringent criteria 
are used, such as the presence of a recognizable Mendelian 
inheritance pattern, then FAD comprises an exceedingly 
small percentage (less than 1%) of the total number of AD 
cases. Most Mendelian FAD cases are autosomal dominant Clinical Interventions in Aging 2007:2(3) 349
Alzheimer’s disease pathogenesis
Table 1 Genes implicated in familial autosomal dominant AD
Gene Chromosome  Proportion  of  AD
Amyloid precursor protein  21  ~25 known families
Presenilin 1  14  ~315 known families
Presenilin 2  1  ~18 known families
and have a presenile onset. Nevertheless, even among 
early-onset cases clear-cut autosomal dominant inheritance 
patterns are rare. Despite their rarity, the autosomal dominant 
FAD cases demonstrate genetic heterogeneity, as mutations 
in at least three different genes cause the phenotype (Table 1). 
Therefore, when considering AD pathogenesis, it is perhaps 
expedient to consider the fact that what we now consider 
AD actually appears to consist of multiple pathogenically 
different Alzheimer’s diseases.
Disease of aging versus aging
Alois Alzheimer’s first “Alzheimer’s disease” patient, 
Auguste D., was reported in detail in 1907 (Alzheimer 1907). 
Auguste D. presented early in her sixth decade, and so could 
ofﬁ  cially be considered a case of presenile dementia. On 
autopsy, her brain manifested the plaques and tangles that 
have since been associated with the AD condition. As no 
prior descriptions of plaque and tangle presenile dementia 
existed, the door was open for naming a new disease, which 
was shortly thereafter accomplished by Emil Kraepelin, the 
chairman of Alzheimer’s academic department (Kraepelin 
1910). Simultaneously, Oscar Fischer (1907) at a rival 
institution recognized brains of elderly demented indi-
viduals also contained plaques. In subsequent years the 
medical community assimilated these observations so that 
the presenile tangle-and-plaque dementia was considered 
a disease, AD. The other situation (senile tangle-and-
plaque dementia) was considered a normal part of aging, 
and for many decades hence syndromically referred to as 
senile dementia (Amaducci et al 1986; Boller and Forbes 
1998). In the decades following this, AD remained a rather 
uncommon entity.
While life expectancy increased in westernized countries 
during the course of the twentieth century, senile dementia 
became increasingly prevalent. Interest in treating the 
demented elderly therefore grew, and investigators increas-
ingly noted the similarities between AD and senile dementia. 
As Katzman pointed out in 1976, “neither the clinician, the 
neuropathologist, nor the electron microscopist can distin-
guish between the two disorders, except by the age of the 
patient” (Katzman 1976). It was further argued “Alzheimer 
disease and senile dementia are a single process and should 
therefore be considered a single disease” (Katzman 1976). 
This view justiﬁ  ed making dementia syndrome research a 
national health priority and invigorated research into the phe-
nomenon. Expanding the deﬁ  nition of AD to include those 
with senile dementia swelled the ranks of those diagnosed 
to such an extent it inextricably linked AD to aging. The 
incidence of AD rises with increasing age, so that among 
centenarians the histopathologic and clinical changes needed 
to justify a diagnosis of AD probably coexist in greater than 
75% (Mizutani and Shamada 1992; Thomassen et al 1998; 
Blansjaar et al 2000; Perls 2004; Jicha et al 2005). One oft-
quoted study concluded almost half those over age 85 have 
AD or at least an AD syndrome (Evans et al 1989).
Relevant to this debate are recent data suggesting AD 
may develop in individuals over the course of decades 
(Snowdon et al 1996; Smyth et al 2004). If this view is 
correct, then AD is a disease most people are in the process 
of developing throughout adulthood. From an epidemiologic 
standpoint, therefore, the debate about whether tangle-
and-plaque dementia is a distinct disease or part of aging 
remains unresolved. An in-depth discussion of the aging-AD 
controversy has been reviewed elsewhere (Swerdlow 
2006).
Does the histopathology drive 
the disease, or does the disease 
drive the histopathology?
With AD, the cause-consequence debate goes back to 
Alzheimer’s time. Alzheimer personally believed the histo-
pathologic features he observed were a marker of an upstream 
process and not the root cause of the disease (Davis and 
Chisholm 1999). There are biochemical studies that support 
this view. For example, inhibition of the electron transport 
chain (ETC) enzyme cytochrome oxidase alters amyloid 
precursor protein (APP) processing to an amyloidogenic 
derivative (Gabuzda et al 1994). Oxidative stress activates 
beta secretase (BACE) activity, a requisite event in the pro-
cessing of APP to Aβ (Tamagno et al 2002). Data such as 
these suggest amyloidosis in AD is a secondary event.
On the other hand, it is clear AD sometimes represents 
a primary amyloidosis. In 1991, APP gene mutation was 
shown to cause an early-onset, autosomal dominant AD 
variant (Goate et al 1991). Mutation of two other genes, 
presenilin 1 and presenilin 2, were subsequently found to 
also cause early-onset, autosomal dominant AD (Levy-
Lahad et al 1995; Sherrington et al 1995). Functional studies Clinical Interventions in Aging 2007:2(3) 350
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revealed these mutations alter APP processing. In each case, 
Aβ42 to Aβ40 ratios increase (Scheuner et al 1996).
Whether most AD represents a primary or secondary 
amyloidosis goes to the heart of the AD pathogenesis debate. 
Two pathogenic AD hypotheses are discussed below, the 
amyloid cascade hypothesis (which assumes AD is always a 
primary amyloidosis), and the mitochondrial cascade hypoth-
esis (which assumes most AD is a secondary amyloidosis).   
The amyloid cascade hypothesis
The cortical plaques of AD brains largely consist of Aβ pro-
tein. Aβ is produced via processing of its parent protein, APP. 
The gene encoding APP resides on chromosome 21. Speciﬁ  c 
APP physiologic roles are not entirely clear, but in a general 
sense it is felt to contribute to proper neuronal function and 
perhaps cerebral development (Zheng et al 1995).
Because plaques contain Aβ and Down’s syndrome 
patients with trisomy 21 manifest both plaque pathology 
and presenile cognitive decline below their baseline, the 
role of the APP gene in AD was previously considered. In 
1991, an APP gene mutation was uncovered in a family with 
autosomal dominant, early onset AD (Goate et al 1991). Soon 
after this, the amyloid cascade hypothesis was formulated. In 
its original form, the amyloid cascade hypothesis proposed 
altered APP processing drove Aβ production, Aβ gave rise 
to plaques, plaques induced neurodegeneration, and this 
neuronal loss resulted in the clinical dementia syndrome 
typical of AD (Hardy and Allsop 1991; Hardy and Higgins 
1992).
While subsequent research failed to show APP mutation 
was a common cause of AD, the ﬁ  ndings of other genetic 
and molecular research also lent support to the amyloid 
cascade hypothesis. Speciﬁ  cally, mutations in two other 
genes, presenilin 1 on chromosome 14 and presenilin 2 
on chromosome 1, were also shown to cause variants of 
early onset, autosomal dominant AD (Levy-Lehad et al 
1995; Sherrington et al 1995). While the functional role 
of presenilin proteins was unknown at the time of these 
discoveries, it was nevertheless found that as was the 
case with APP mutations, presenilin mutations enhanced 
production of the 42 amino acid APP C-terminal degrada-
tion product (Aβ42) at the expense of the 40 amino acid 
C-terminal APP C-terminal degradation product (Aβ40) 
(Scheuner et al 1996). Aβ42 is toxic to cells in culture, 
prone to aggregation, and found in plaques. More recent 
data suggest the presenilin gene products comprise part of 
the γ-secretase complex that is so intimately involved in 
APP processing (Wolfe et al 1999; Kimberly et al 2000).
The amyloid cascade hypothesis (Figure 1) has 
substantially evolved since its initial formulation. While Aβ 
sequestered in plaques was at ﬁ  rst proposed to represent the 
critical toxic species, more recent versions of the hypoth-
esis assume Aβ that is not sequestered in plaques actually 
drives the disease (Lesne and Kotilinek 2005; Walsh et al 
2005). Even so, the amyloid cascade hypothesis seems most 
applicable in cases of early onset, autosomal dominant AD. 
Certainly, these cases are the ones most likely to represent a 
primary amyloidosis. Such cases comprise far less than 1% 
of AD, though, and it is not clear whether it is reasonable to 
etiologically extrapolate to the late-onset form (which afﬂ  icts 
the vast majority of those affected). Whether individuals with 
late-onset AD also carry genetic variations that promote a 
primary Aβ amyloidosis remains to be shown. If this turns 
out not to be the case, the possibility that amyloidosis in 
late-onset AD is secondary to a more upstream event will 
require consideration.
Pursuit of the amyloid cascade hypothesis has yielded 
in depth insight into how APP processing actually occurs. 
Enzymes are capable of cutting APP in several places near 
its C-terminal end. One group of enzymes called α-secretases 
cut APP 83 amino acids from its carboxyl terminus. Enzymes 
with α-secretase activity include the ADAM (“A Disintegrin 
and Metalloproteinase”) protease family. The β-secretase 
enzymes consist of at least two different complexes named 
BACE1 and BACE2. The BACE enzymes cut APP 99 amino 
acids from the carboxyl terminus. The third type of APP cut 
is rendered by the γ-secretase enzyme complex. The catalytic 
function of γ-secretase is mediated by either presenilin 1 or 
presenilin 2. The γ-secretase cuts APP twice. One of these 
cuts occurs 50 amino acids from the APP carboxyl terminus. 
This generates a 50 amino acid peptide consisting of the 
extreme APP C-terminal end, which is titled the amyloid 
intracellular domain (AICD). The other γ-secretase cut is 
somewhat variable, but tends to occur 57, 59, or 61 amino 
acids from the APP C-terminus.
The APP secretases work in combination. Sequential 
processing by the α and γ-secretases results in a large 
N-terminal peptide called soluble APPα (sAPPα) and a 
smaller 3 kD peptide called P3. Proteolysis by enzymes 
with α-secretase activity precludes sequential β-γ secretase 
activity. When both the β and γ secretases process APP, the 
β-secretase cut produces a large N-terminal peptide called 
soluble APPβ (sAPPβ), as well as a smaller C-terminal 
fragment called CTFβ. The γ-secretase cuts CTFβ, and the 
more upstream (from the APP carboxyl terminus) 4 kD 
peptide deﬁ  ned by the γ and β secretases is the Aβ peptide. Clinical Interventions in Aging 2007:2(3) 351
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With sequential β-γ secretase activity the exact γ secretase 
cut site varies, yielding an Aβ peptide which is typically 
38–43 amino acids.
Aβ degradation is also enzymatically mediated. Enzymes 
that degrade Aβ include neprilysin and insulin degrading 
enzyme (IDE). Interestingly, in the common non-autosomal 
dominant forms of AD Aβ overproduction is accompanied 
by IDE downregulation (Cook et al 2003). This suggests 
amyloidosis in AD is not a toxic accident, but rather part 
of a coordinated cell response to an upstream event. Deﬁ  n-
ing this event could potentially drive further evolution of 
the amyloid cascade hypothesis. As it currently stands, the 
amyloid cascade hypothesis assumes all AD is a primary 
amyloidosis. This assumption is extrapolated from a handful 
of AD cases which almost certainly are primary amyloidoses. 
If an upstream event is shown to initiate AD amyloidosis, 
though, it would suggest amyloidosis in the vast majority 
of AD cases is a secondary event. Taking this argument one 
step further, some have even argued amyloidosis in AD not 
only represents a secondary event, but also a compensatory 
one (Castellani et al 2006).
Other clues to AD pathogenesis
Plaque-oriented research dominates the AD field. Much 
investigation, though, has focused on neurofibrillary 
tangles. These intracellular aggregations contain abnormally 
configured, excessively phosphorylated tau protein. In 
differentiated cells tau is normally unphosphorylated. It 
associates with microtubule cytoskeleton elements. This differs 
from undifferentiated cells, in which microtubules and tau do 
not form a permanent cytoskeleton and tau is phosphorylated. 
Mutations in the tau gene are associated with familial 
frontotemporal dementia, especially in cases with concomitant 
parkinsonism and tangle histopathology (Neary et al 2005). 
Thus, while primary tauopathy can drive neurodegeneration, 
it is not recognized to cause an AD phenotype. 
Interestingly, AD brains exhibit neuronal cell cycle 
re-entry (Vincent et al 1996; McShea et al 1999; Arendt et al 
2000; Yang et al 2001; Bowser and Smith 2002; Zhu et al 
2004). Cell cycle re-entry refers to a phenomenon in which 
differentiated, non-dividing cells manifest molecular changes 
typically associated with cell division. These manifestations 
include an increase in cyclin-dependent kinase (CDK) activi-
ties and DNA content. Cell cycle re-entry produces aneuploid 
neuronal nuclei with replicated chromosomes. AD neurons 
can actually reach G2, the penultimate stage of the cell cycle 
that immediately precedes mitosis (M). Nevertheless, these 
neurons are unable to complete mitosis, which leaves them 
in a state called G2-M arrest.
CDK proteins also phoshorylate tau. It is tempting to 
speculate tau phosphorylation and cell cycle re-entry pathology 
are related. A mechanistically critical relationship between 
Figure 1 The amyloid cascade hypothesis.  A black box is shown in the middle of the ﬁ  gure, since mechanisms through which Aβ42 drives downstream pathology are not 
well deﬁ  ned. 
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cell-cycle re-entry, oxidative stress, and neuronal demise was 
recently postulated (Zhu et al 2004).
As discussed above, AD and aging are epidemiologi-
cally intertwined. The strength of this relationship suggests 
these processes share mechanistic commonalities. Clini-
cally, AD is not an all-or-nothing entity. It is a continuum. 
Mild, moderate, and severe stages are arbitrarily deﬁ  ned. 
Preceding AD proper is a recognizable transition phase, 
MCI. Neuropsychological testing now suggests MCI is 
itself preceded by a period of cognitive change (reviewed in 
Swerdlow 2006). Some call this period pre-MCI (Swerdlow 
2006). Pre-MCI may last decades; some data suggest it starts 
early in adulthood (Snowdon et al 1996; Smyth et al 2004). 
Pre-MCI may provide a conceptual framework for “cogni-
tive reserve” phenomena in AD (Stern 2006). Those with 
higher education levels, a cognitive reserve surrogate, are 
said to have reduced AD risk. It is heuristically reasoned 
high cognitive reserve individuals begin their decades-long 
cognitive decline further from the dementia ﬁ  nish line than 
low cognitive reserve individuals. Given equal pre-MCI 
cognitive decline trajectories, low cognitive reserve indi-
viduals will cross dementia thresholds before high cognitive 
reserve individuals. Pre-MCI decline trajectories, though, 
probably vary between individuals. A combination of genetic 
and environmental factors may inﬂ  uence decline trajectories. 
By this reasoning, those with the most cognitive reserve and 
slowest decline trajectories are more likely to develop clinical 
AD at older ages than those with less cognitive reserve and 
faster decline trajectories (Figure 2).
Apolipoprotein E (APOE) alleles influence AD 
related-markers in ways potentially relevant to pre-MCI 
cognitive decline trajectories (Small et al 1995; Reiman et al 
1996; Caselli et al 1999). The APOE gene on chromosome 
19 encodes a protein, apolipoprotein E, which was previ-
ously recognized to play a role in cholesterol transport. Three 
APOE alleles are distributed throughout the population. 
Among these, the APOE4 allele associates with a younger 
age of AD onset than the APOE3 or APOE2 alleles (Corder 
et al 1993; Locke et al 1995; Blacker and Tanzi 1998). For 
perhaps this reason APOE4 is also associated with a greater 
lifetime AD risk. The underlying biochemical basis for this 
association is unknown, but hypotheses abound (Saunders 
2000). The cysteine to arginine substitutions that deﬁ  ne 
APOE4 may minimize any inherent ability of the protein 
to mitigate oxidative stress (Miyata and Smith 1996). 
Apolipoprotein E protein variations may affect cholesterol 
transport, thereby indirectly affecting amyloidosis (Poirier 
2000). Direct effects on Aβ cerebrovascular transport might 
explain the association (DeMattos et al 2002; Zlokovic 
et al 2005). Apoliprotein E fragments also accumulate in 
mitochondria and affect mitochondrial function (Chang 
et al 2005). Apolipoprotein E4 produces more of these toxic 
fragments than apolipoprotein E3.
Mitochondrial dysfunction clearly exists in AD subjects 
(Parker et al 1990; reviewed in Swerdlow and Kish 2002). 
Structural and functional changes are evident. Mitochon-
drial pathology in AD is not limited to the brain. Mito-
chondria are implicated in aging, amyloidosis, oxidative 
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stress, tau phosphorylation, and cell cycling. The protean 
manifestations of mitochondrial dysfunction and systemic 
nature of mitochondrial dysfunction in AD suggest to some 
a central pathogenic role for these organelles (Parker et al 
1990; Swerdlow and Khan 2004).
The mitochondrial cascade 
hypothesis
The mitochondrial cascade hypothesis attempts a uniﬁ  ed 
explanation for the clinical, biochemical, and histologic 
features of AD (Swerdlow and Khan 2004). The mitochon-
drial cascade hypothesis takes several conceptual liberties. 
It assumes similar physiologic mechanisms underlie AD 
and brain aging. It postulates because AD mitochondrial 
dysfunction is systemic, it cannot simply represent a con-
sequence of neurodegeneration. The mitochondrial cascade 
hypothesis argues non-Mendelian genetic factors contribute 
to non-autosomal dominant AD. Finally, it posits AD brain 
mitochondrial dysfunction drives amyloidosis, tau phos-
phorylation, and cell cycle re-entry.
Certainly, mitochondria are indirectly featured in past the-
ories of aging and directly in current aging theory. The rate of 
living hypothesis arose in the 1920’s from observations that 
animals with low metabolic rates tend to outlive those with 
high metabolic rates (Pearl 1928). Harman reﬁ  ned this when 
he proposed the free radical theory of aging in 1956 (Harman 
1956). The free radical theory of aging speciﬁ  cally postulated 
over time cells accumulate structural damage from oxidative 
byproducts. By the 1970’s mitochondria were recognized 
sites of free radical production, and for many the free radi-
cal theory of aging morphed into the mitochondrial theory 
of aging (Harman 1972; Miquel et al 1980). The late 1980’s 
envisaged a role for somatic mitochondrial DNA (mtDNA) 
damage in aging (Linnane et al 1989; Wallace 1992). Cor-
roborating this possibility are recent studies showing mtDNA 
mutation acquisition accelerates aging in laboratory animals 
(Trifunovic et al 2004; Kujoth et al 2005).
Mitochondrial dysfunction is observed in multiple AD 
tissues (reviewed in Swerdlow and Kish 2002). At least 
brain, platelet, and ﬁ  broblast mitochondria are involved. 
Defects of three mitochondrial enzymes are reported. This 
includes reduced activities of pyruvate dehydrogenase 
complex, alpha ketoglutarate dehydrogenase complex, and 
cytochrome oxidase (Gibson et al 1998). Spectral analysis 
of cytochrome oxidase indicates AD brains contain normal 
amounts of cytochrome oxidase, but the enzyme itself is 
structurally altered (Parker and Parks 1995). Various mecha-
nisms, such as oxidative stress and proteasome dysfunction, 
have been postulated to facilitate mitochondrial dysfunction 
in neurodegenerative diseases such as AD (Ding et al 2006). 
Also, cytoplasmic hybrid (cybrid) studies indicate mtDNA at 
least in part accounts for reduced cytochrome oxidase activity 
in AD, and through this perhaps oxidative stress (reviewed 
in Swerdlow 2007).
Cybrid studies involve transfer of exogenous mtDNA to 
cultured cells depleted of endogenous mtDNA (reviewed in 
Khan et al 2006). “ρ” DNA is an alternative term for mtDNA. 
These mtDNA-depleted cells are therefore called ρ0 cells. 
They do not produce mtDNA-encoded proteins and lack 
cytochrome oxidase activity. Mitochondrial DNA transferred 
to ρ0 cells replicates and accomplishes mtDNA replacement. 
This enables expression of mtDNA-encoded ETC subunits 
and restoration of cytochrome oxidase activity. When cybrid 
lines containing mtDNA from AD subject platelets are com-
pared to cybrid lines containing mtDNA from age-matched 
controls without AD, cytochrome oxidase activity is lower in 
the cybrid lines containing AD subject mtDNA (Swerdlow 
et al 1997; reviewed in Swerdlow 1997). Because nuclear 
genetic and cell culture conditions are equivalent between 
all cybrid cell lines, differences between mtDNA from the 
donor subjects likely account for the observed differences 
in cytochrome oxidase activity.
The exact nature of the implied AD cybrid-control cybrid 
mtDNA difference is unclear. This uncertainty is partly due 
to mtDNA-related complexities. Mitochondrial genetics and 
nuclear genetics differ in several key ways. One difference 
is that cells contain multiple copies of mtDNA. The mtDNA 
molecules within a cell can be identical, a state referred 
to as homoplasmy. However, the nucleotide sequences of 
mtDNA molecules within a cell can also vary. This is called 
heteroplasmy. If mtDNA sequence variation is present within 
a cell, it is necessary to consider whether it represents a homo-
plasmic or heteroplasmic variation. If the variation is hetero-
plasmic, it is necessary to further consider whether it represents 
a majority (high abundance heteroplasmy) or minority (low 
abundance heteroplasmy) of that cell’s mtDNA copies.
Distinct homoplasmic or high abundance heteroplasmic 
mutations of mtDNA cytochrome oxidase (CO) likely 
account for at most a very small percentage of AD (Hamblet 
et al 2006), and therefore should not account for AD-control 
cybrid differences. Mitochondrial DNA polymorphisms 
could potentially account for AD-control cybrid differences, 
as these are a common source of mtDNA inter-individual 
variability. Although AD-mtDNA polymorphism associa-
tions are reported (Chagnon et al 1999; reviewed in Swerdlow 
and Kish 2002; van der Walt et al 2004), the effect of speciﬁ  c Clinical Interventions in Aging 2007:2(3) 354
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polymorphisms or linked polymorphisms (haplogroups) 
on cybrid cytochrome oxidase activity is unstudied. Low 
abundance heteroplasmy might also cause AD-control cybrid 
cytochrome oxidase differences. A recent study did in fact 
suggest unique low abundance mtDNA heteroplasmies 
occur in AD (Coskun et al 2004). Other data indicate low 
abundance mtDNA heteroplasmies manifest with increasing 
age, and these heteroplasmies are associated with reduced 
cytochrome oxidase activity (Lin et al 2002). However, the 
presence and role of low abundance mtDNA heteroplasmies 
in AD cybrids has not been critically evaluated.
Whether somatic or inherited mtDNA features account 
for AD-control cybrid cytochrome oxidase differences also 
requires consideration. Data pertinent to this question permit 
speculation. First, complex I activity is normal in AD cybrids 
(Ghosh et al 1999). Complex I contains seven mtDNA-
encoded subunits. Absence of complex I dysfunction suggests 
somatic mutation does not account for reduced cytochrome 
oxidase activity in AD cybrids, since acquired mtDNA 
somatic mutation should also reduce complex I activity. 
Second, reduction of cytochrome oxidase activity in multiple 
non-degenerating tissues is more consistent with mtDNA 
inheritance than somatic mutation. Third, plotting one AD 
cybrid study’s cytochrome oxidase data by mtDNA donor age 
actually reveals the youngest AD subjects show the biggest 
activity reductions (Figure 3). These data suggest mtDNA 
signatures might affect intrinsic cognitive decline trajectories. 
One interpretation of this is the lower the cytochrome oxidase 
activity, the sooner the subject reaches the dementia threshold. 
Epidemiologic data showing maternal AD status correlates 
better with offspring AD status than paternal AD status is 
consistent with this possibility (Edland et al 1996).
Any comprehensive theory of AD pathogenesis must 
explain the different pathologies observed in Alzheimer’s 
disease. AD cybrids with reduced cytochrome oxidase 
activity overproduce Aβ42 and Aβ40 (Khan et al 2000). 
Under in vitro conditions sodium azide, a cytochrome oxidase 
inhibitor, alters APP processing towards amyloidogenic path-
ways (Gabuzda et al 1994). Administering sodium azide to 
mice also causes tau phosphorylation (Szabados et al 2004). 
Fibroblasts from FAD subjects phosphorylate tau following 
exposure to CCCP, a mitochondrial uncoupler (Blass et al 
1990). Mitochondrial ETC dysfunction increases free radical 
production (reviewed in Swerdlow 2002). Enhanced reliance 
on anaerobic metabolism is associated with cell cycling 
(reviewed in Swerdlow and Khan 2004).
Interestingly, Aβ inhibits ETC activity in general and cyto-
chrome oxidase activity speciﬁ  cally (Periera et al 1998; Casley 
et al 2002; Crouch et al 2005; Devi et al 2006). Therefore, a 
reciprocal relationship exists between mitochondrial function 
and amyloidosis. Several independent observations reinforce 
this concept. Neuronal-like NT2 human teratocarcinoma 
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cells exposed to Aβ show high rates of demise. NT2 
ρ0 cells, though, are impervious to Aβ (Cardoso et al 2001). 
The main difference between native NT2 cells and NT2 ρ0 
cells is the absence of a functional ETC in the ρ0 cells. This 
suggests under cell culture conditions the mitochondrial 
ETC mediates Aβ toxicity. Also, APP, Aβ, and the entire 
γ-secretase complex are found either within mitochondria or 
mitochondrial membranes (Anandtheerthavarada et al 2003; 
Lustbader et al 2004; Hansson et al 2004; Crouch et al 2005; 
Manczak et al 2006). The role APP, Aβ, and γ-secretase play 
in mitochondrial function is currently unknown. Recent work 
showing oligomeric β-sheet proteins permeabilize membranes 
(Glabe and Kayed 2006) raises the possibility these proteins 
allow cells to disable mitochondria when certain conditions are 
met. If mitochondrial dysfunction is one of these conditions, 
one physiologic role of APP or Aβ may be to “shut down” 
abnormal mitochondria.
The mitochondrial cascade hypothesis takes aging 
phenomena into account, and applies to individuals long 
before they develop AD. The hypothesis postulates among 
individuals, inherited ETC differences influence mito-
chondrial durability. More durable mitochondria maintain 
adequate function longer than less durable mitochondria, and 
this in part determines aging success. Eventually, though, 
the balance between aerobic and anaerobic metabolism 
is not sustainable. At this point various cell responses are 
triggered. Cell cycle re-entry occurs. Tau phosphorylation 
ensues as neurons commit to de-differentiation. Amyloido-
sis facilitates this commitment by further altering aerobic 
metabolism. Ultimately, the neuronal de-differentiation 
response fails. Neurodegeneration results.
Just as the mitochondrial cascade hypothesis identiﬁ  es 
with aging theory, links to the amyloid cascade hypothesis 
are postulated. In early onset, autosomal dominant AD 
altered APP or Aβ physiology initiate pathogenesis. If 
altered APP or Aβ physiology inadvertently induces mito-
chondrial dysfunction, it would trigger the same series of 
events as aging. Mitochondrial failure may therefore repre-
sent a ﬁ  nal common pathway between autosomal dominant 
AD and non-autosomal dominant AD. Such would explain 
the clinical and histologic similarities observed between the 
different Alzheimer’s diseases (Figure 4).
Treatment development and 
clinical trials: Critical assessments 
of pathogenic hypotheses?
Current drug development strategies fall broadly into one 
of two categories. The ﬁ  rst category includes treatments 
speciﬁ  cally designed to reduce the burden of brain Aβ. The 
second category includes all other strategies.
In order to reduce brain amyloid levels, approaches to 
both reducing Aβ production and enhancing its removal are 
undergoing evaluation. As discussed above, Aβ is produced 
through the β and γ-secretase mediated processing of APP. 
β-secretase inhibitors have gone to phase II human trials. 
Agents that speciﬁ  cally inhibit γ-secretase could prove prob-
lematic from a side effect perspective, as γ-secretase is also 
critical for processing Notch3, a protein of developmental 
importance and perhaps brain maintenance. Notch3 muta-
tions cause another dementia syndrome, cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leuko-
encephalopathy (CADASIL).
Certain NSAIDS (ibuprofen and ﬂ  urbiprofen) inﬂ  uence 
the γ-secretase but do not inhibit it outright. In general, these 
“selective amyloid lowering agents” (SALAs) alter where 
γ-secretase cuts the APP protein. Under in vitro conditions, 
ibuprofen and ﬂ  urbiprofen reduce production of the Aβ42 
APP derivative, with a secondary increase in the production 
of shorter Aβ fragments (Ericksen et al 2003). An enantiomer 
of ﬂ  urbiprofen, R-ﬂ  urbiprofen, recently completed a phase II 
human trial and is slated for a phase III efﬁ  cacy trial.
Immunotherapy approaches have been studied as a way 
to enhance Aβ removal. The most extensive investigation 
involved AN1792, an Aβ-based vaccine (Aβ linked to an 
adjuvant). This vaccine ﬁ  rst showed efﬁ  cacy in transgenic mice 
that produce human Aβ. Such transgenic mice are engineered 
to express human APP transgenes containing mutations known 
to cause autosomal dominant, early-onset AD, and are widely 
used for preclinical drug screening in AD. In vaccinated mice, 
Aβ loads were reduced, there was preservation of cognitive 
abilities, and the vaccine was well tolerated (Schenk et al 
1999). When phase I human studies did not reveal obvious tox-
icity, a phase II trial was initiated. This trial was prematurely 
halted after a substantial percentage of those mounting a robust 
immune response to the vaccine experienced encephalitis, a 
potentially life-threatening brain inﬂ  ammation. However, there 
were over 40 individuals in this study who were vaccinated, 
developed a robust immune response, and did not develop 
encephalitis. Most of these subjects, as well as the trial’s place-
bo group, received ongoing clinical follow-up. One-year post-
vaccination neuropsychological data on these subjects have 
been published (Gilman et al 2005). On no single endpoint 
was a statistical beneﬁ  t shown. Subjects in both treatment and 
placebo groups continued to decline. For most of the individual 
endpoints, trends towards lesser decline in the vaccination 
group were identiﬁ  ed, and on a z score analysis these trends Clinical Interventions in Aging 2007:2(3) 356
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were signiﬁ  cant, suggesting it was possible the vaccine group 
was progressing slightly more slowly than the placebo group. 
Other data pertinent to the AN1792 study derive from autop-
sies of vaccinated subjects that subsequently died for various 
reasons. Brain histopathology from these deceased subjects 
demonstrated clear-cut reductions in brain parenchyma Aβ 
(Nicoll et al 2003; Ferrer et al 2004; Masliah et al 2005). To 
summarize the AN1792 experience from an efﬁ  cacy perspec-
tive, available clinical data are inconclusive, but indicate over 
a one-year period activating the immune system to remove Aβ 
does not have a robust impact on cognition.
The next generation of amyloid clearance therapies are 
currently under development. These include modiﬁ  cations 
of the active immunization approach that will hopefully not 
trigger encephalitis. Passive immunization approaches via 
antibody infusions are also under investigation. The use of 
unique Aβ antibodies is being explored. The utility of treating 
AD subjects with intravenous immunoglobulin preparations, 
which naturally contain antibodies to Aβ, is being evaluated 
in an open label study (Relkin et al 2005).
The second category of AD treatment development 
includes efforts not speciﬁ  cally intended to reduce brain Aβ 
levels. For example, neuroscientists are unraveling intracel-
lular pathways involved in cell information processing, and 
drugs that can modulate these pathways are under consid-
eration. Drugs that retard neuroﬁ  brillary tangle formation 
in mice expressing mutant human tau transgenes, such as 
valproic acid, are being tested in humans. Although standard 
antioxidants to date have shown no-to-minimal evidence of 
therapeutic efﬁ  cacy, new antioxidants that target speciﬁ  c 
free radical production sites are in preclinical development 
(Reddy 2006). The thiazolidinedione drugs rosiglitazone and 
pioglitazone, which reduce insulin resistance and which may 
also have anti-inﬂ  ammatory effects, are undergoing testing in 
humans with AD (Risner et al 2006; Geldmacher et al 2006). 
One small open label trial has involved intracranial implanta-
tion of ﬁ  broblasts engineered to produce neurotrophic factors 
(Tuszynski et al 2005).
Obviously, successful development of new AD treatments 
depends on elucidating AD’s true underlying pathophysiology. 
If AD is a primary amyloidosis, as is postulated by the amyloid 
cascade hypothesis, then reducing Aβ would seem a rationale 
way to proceed with drug development. If AD is not a primary 
amyloidosis, then the impact anti-amyloid therapies have on 
the disease will be limited at best. Moreover, if AD is not a 
primary amyloidosis, the usefulness of Aβ-overproducing 
transgenic animals for preclinical drug testing is called into 
question. Finally, at genetic and epidemiologic levels it is 
now possible to deﬁ  ne several different Alzheimer’s diseases. 
It is reasonable to consider whether treatments useful in one 
type of AD may not beneﬁ  t patients with another type. In any 
case, Aβ-oriented treatment development will likely provide 
a practical assessment of the amyloid cascade hypothesis. If 
treatments that efﬁ  ciently reduce Aβ production or remove Aβ 
fail to arrest disease progression, it would argue amyloidosis 
is not the primary pathology in most of those with AD.
Conclusion
Unlike many recent AD reviews, this one assumes critical 
questions remain about AD pathogenesis. As AD now stands, 
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there are at least several different Alzheimer’s diseases. The 
rare autosomal dominant forms are primary amyloidoses. 
Amyloidosis in the common age-related forms may prove 
secondary. Until the causes of Aβ accumulation in age-related 
AD are revealed, it seems wise not to assume Aβ aggregation 
drives the disease, or that Aβ removal will cure it.
AD is now associated with increasing numbers of 
clinical, biochemical, and histologic markers. The ﬁ  delity 
of these associations, though, does not necessarily address 
pathogenesis. After all, it would be wrong to conclude serum 
troponin causes myocardial infarcts simply because levels 
are consistently elevated in myocardial infarct states. On 
the other hand, the more AD phenomena we recognize, the 
more likely it is the pieces of the AD puzzle will one day 
come together.
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